# EDGAR Filing Document

**Accession Number:** 0000948320
**File Stem:** 0001493152-26-009380
**Filing Date:** 2026-3
**Character Count:** 35127
**Document Hash:** 96c247f6eed740ed2360d3efa37b6124
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-009380.hdr.sgml**: 20260309

**ACCESSION NUMBER**: 0001493152-26-009380

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 42

**CONFORMED PERIOD OF REPORT**: 20260309

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260309

**DATE AS OF CHANGE**: 20260309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LifeMD, Inc.
- **CENTRAL INDEX KEY:** 0000948320
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 760238453
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39785
- **FILM NUMBER:** 26735646

**BUSINESS ADDRESS:**
- **STREET 1:** 236 FIFTH AVENUE
- **STREET 2:** SUITE 400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001
- **BUSINESS PHONE:** (866) 351-5907

**MAIL ADDRESS:**
- **STREET 1:** 236 FIFTH AVENUE
- **STREET 2:** SUITE 400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CONVERSION LABS, INC.
- **DATE OF NAME CHANGE:** 20180622

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Immudyne, Inc.
- **DATE OF NAME CHANGE:** 20120514

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMMUDYNE INC
- **DATE OF NAME CHANGE:** 19950720

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 9, 2026**

**<u>LIFEMD, INC.</u>**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39785** | **76-0238453** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

**<u>236 Fifth Avenue, Suite 400</u>**

**<u>New York, NY 10001</u>**

**(Address of principal executive offices, including zip code)**

**<u>(866) 351-5907</u>**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | LFMD | The Nasdaq Global Market |
| 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share | LFMDP | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition.**

On March 9, 2026, LifeMD, Inc. (the "Company") issued a press release announcing its financial results for the three months and year ended December 31, 2025, and its earnings guidance for 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

**Item 7.01. Regulation FD Disclosure.**

The Company hereby furnishes an investor presentation (the "Presentation"), which it expects to use in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others commencing on March 9, 2026. The Presentation is furnished herewith as Exhibit 99.2 and may also be found on the Company's website at https://lifemd.com.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this Current Report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information in this Current Report on Form 8-K (including Exhibits attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

**Cautionary Note Regarding Forward-Looking Statements**

This Current Report on Form 8-K includes information that may constitute forward-looking statements. These forward-looking statements are based on the Company's current beliefs, assumptions, and expectations regarding future events, which in turn are based on information currently available to the Company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. Forward-looking statements include, without limitation, statements relating to projected industry growth rates, the Company's current growth rates and the Company's present and future cash flow position. A variety of factors could cause actual events and results, as well as the Company's expectations, to differ materially from those expressed in or contemplated by the forward-looking statements. Risk factors affecting the Company are discussed in detail in the Company's filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

**Item 9.01. Exhibits.**

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit** |
| 99.1 | [Press Release dated March 9, 2026](ex99-1.htm) |
| 99.2 | [Investor Presentation dated March 9, 2026](ex99-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **LIFEMD, INC.** | **LIFEMD, INC.** |
| Dated: | March 9, 2026 | By: | */s/ Marc Benathen* |
|  |  |  | Marc Benathen |
|  |  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**LifeMD Reports Fourth Quarter and Full Year 2025 Results**

● Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million.

● Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.

● Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy and Q1 sign-ups at record levels.

● Exited 2025 with $36.8 million of cash and no debt, positioning LifeMD for accelerated investments in growth.

● Benefits infrastructure on track to cover approximately 220 million Americans in second quarter; women's health offering seeing strong early patient growth.

***Conference call begins at 4:30 p.m. Eastern time today***

**NEW YORK, March 9, 2026 —** <u>LifeMD, Inc.</u> (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the fourth quarter and year ended December 31, 2025.

**Management Commentary**

"LifeMD delivered strong fourth quarter results across all business lines and is entering its next phase of growth," said Justin Schreiber, Chairman and CEO of LifeMD. "Our strategy of building a trusted and sustainable platform for virtual healthcare delivery is gaining momentum. Our weight management business is seeing record patient sign-ups in the first quarter at attractive acquisition costs. More than 100 million Americans are clinically eligible for GLP-1 therapy, yet only a fraction are currently being treated—a generational opportunity. Subsequent to year end, we launched oral Wegovy to help patients overcome real barriers around cost, access, and ongoing clinical support. With multiple catalysts ahead—including Medicare coverage for GLP-1 medications, expanded collaborations with GLP-1 manufacturers, and an infrastructure that supports both self-pay and insurance—LifeMD is uniquely positioned for long-term leadership in this transformative market.

<br> "Beyond weight management, our highly differentiated specialty offerings continue to scale. Rex MD, our men's health brand, delivered strong, profitable growth and recently launched oral Wegovy. Our women's health business, focused on menopause, hormonal, and bone health, is seeing encouraging early patient growth and represents a deeply underserved population we are uniquely equipped to help. Underpinning all of this is a virtual care infrastructure that we believe sets LifeMD apart and positions the Company for success in the years to come: a 50-state medical benefits infrastructure expected to cover 220 million Americans by end of the second quarter, a highly specialized affiliated provider group, and a national affiliated pharmacy operation. This foundation, combined with unique and growing collaborations with some of the largest healthcare and pharmaceutical brands in the world, uniquely positions LifeMD to capture significant growth in 2026 and the years ahead," concluded Mr. Schreiber.

"In our first quarter as a pure-play telehealth business, LifeMD delivered solid results with 4% revenue growth and a 348% increase in adjusted EBITDA. Our balance sheet has never been stronger—we exited the year with nearly $37 million in cash and no debt. This financial strength is a key asset as we invest aggressively in the expansion of our rapidly growing and diversifying platform. Our 2026 guidance reflects these investments, with annualized run-rate revenue expected to exceed $250 million and annualized adjusted EBITDA expected to exceed $25 million by the fourth quarter of 2026," said Marc Benathen, LifeMD's Chief Financial Officer.

**Fourth Quarter Financial Highlights**

All comparisons are with the fourth quarter of 2024. Non-GAAP financial measures referenced below are defined and reconciled to GAAP financial measures at the end of this press release.

● Total revenue increased 4% to $46.9 million.

● The number of active telehealth subscribers increased 16% to approximately 323,000 at quarter end.

● Gross margin expanded to 87%, up from 81% in the prior-year period, reflecting favorable revenue mix.

● GAAP net loss from continuing operations attributable to LifeMD, Inc. common stockholders was $1.9 million or $0.04 per share compared to a net loss from continuing operations attributable to LifeMD, Inc. common stockholders of $6.8 million or ($0.16) per share in the prior-year period.

● Including income from discontinued operations related to the sale of WorkSimpli, net income totaled $19.2 million, or $0.41 per share.

● Adjusted EBITDA was $4.8 million compared to $1.1 million in the prior-year period.

● Cash totaled $36.8 million as of December 31, 2025 and the Company had no debt as of year-end 2025.

**Fourth Quarter Key Performance Metrics**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended Dec. 31,** | **Three Months Ended Dec. 31,** | **Y-o-Y** | **Twelve Months Ended Dec. 31,** | **Twelve Months Ended Dec. 31,** | **Y-o-Y** |
| **($ in 000s)**<br>**Key Performance Metrics** | **2025** | **2024** | **% Growth** | **2025** | **2024** | **% Growth** |
| **<u>Revenue</u>** |  |  |  |  |  |  |
| Revenue | $46868 | $45137 | 4% | $194055 | $154824 | 25% |
| Adjusted EBITDA | $4759 | $1062 | 348% | $15254 | $3726 | 309% |
| Active Subscribers | 322872 | 277739 | 16% | 322872 | 277739 | 16% |

---

**Financial Guidance**

For the first quarter of 2026, the Company expects:

● Revenue in the range of $48 million to $49 million.

● Adjusted EBITDA loss of $4 million to $5 million, reflecting strategic front-loaded patient acquisition investment spend as the number of GLP-1 patient sign-ups doubled versus Q4 2025.

● Adjusted EBITDA expected to return to profitability in Q2 as customer acquisition costs decline sequentially and the substantial rise in patient volumes becomes accretive for the balance of 2026.

For the full year 2026, the Company expects:

● Revenue in the range of $220 million to $230 million, representing 13% to 19% year-over-year growth. Annualized run-rate revenue expected to exceed $250 million by Q4 2026, driven by GLP-1 and women's health momentum.

● Adjusted EBITDA in the range of $12 million to $17 million. Annualized run-rate adjusted EBITDA expected to exceed $25 million by Q4 2026, with substantial second-half accretion as weight management and women's health investments mature.

**Conference Call**

LifeMD's management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company's financial results and outlook, and answer questions. Details for the call are as follows:

Toll-free dial-in number: 800-343-5172 <br> International dial-in number: 203-518-9856 <br> Conference ID: LIFEMD

A live and archived webcast will be available in the Investors section of the Company's website at <u>ir.lifemd.com</u>.

**About LifeMD, Inc.**

LifeMD<sup>®</sup> is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit <u>LifeMD.com</u>.

**Cautionary Note Regarding Forward Looking Statements**

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: "believe," "expect," "anticipate," "project," "should," "plan," "will," "may," "intend," "estimate," predict," "continue," and "potential," or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, "Risk Factors" identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

**Investor Contact**

Marc Benathen, Chief Financial Officer

<u>marc@lifemd.com</u>

**Media Contact**

Jessica Friedeman, Chief Marketing and Product Officer

<u>press@lifemd.com</u> 

Tables to Follow

++++++

**LIFEMD, INC.**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **December 31, 2025** | **December 31, 2024** |
| **ASSETS** |  |  |
| Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $36786318 | $32651801 |
| &nbsp;&nbsp;&nbsp;Accounts receivable | 9305277 | 10455813 |
| &nbsp;&nbsp;&nbsp;Product deposit | 320217 | 40763 |
| &nbsp;&nbsp;&nbsp;Inventory, net | 2773576 | 2797358 |
| &nbsp;&nbsp;&nbsp;Other current assets | 2646077 | 3003539 |
| &nbsp;&nbsp;&nbsp;Current assets of discontinued operations | - | 3420086 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 51831465 | 52369360 |
| Non-current Assets |  |  |
| &nbsp;&nbsp;&nbsp;Equipment, net | 2444717 | 1439573 |
| &nbsp;&nbsp;&nbsp;Right of use assets, net | 5267857 | 6228559 |
| &nbsp;&nbsp;&nbsp;Capitalized software, net | 10604946 | 9305919 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 262334 | 53336 |
| &nbsp;&nbsp;&nbsp;Non-current assets of discontinued operations | - | 6699550 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Non-current Assets | 18579854 | 23726937 |
| Total Assets | $70411319 | $76096297 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)** |  |  |
| Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $14149154 | $10904671 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 15974016 | 21756619 |
| &nbsp;&nbsp;&nbsp;Current operating lease liabilities | 642422 | 320082 |
| &nbsp;&nbsp;&nbsp;Current portion of convertible long-term debt |  | 8444444 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 10807773 | 17097854 |
| &nbsp;&nbsp;&nbsp;Current liabilities of discontinued operations | - | 8876498 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | 41573365 | 67400168 |
| Long-term Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Convertible long-term debt, net |  | 9885057 |
| &nbsp;&nbsp;&nbsp;Non-current operating lease liabilities | 5681374 | 6279004 |
| &nbsp;&nbsp;&nbsp;Non-current liabilities of discontinued operations | - | 86188 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities | 47254739 | 83650417 |
| Commitments and Contingencies |  |  |
| Stockholders' Equity (Deficit) |  |  |
| &nbsp;&nbsp;&nbsp;Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding as of December 31, 2025 and 2024 | 140 | 140 |
| &nbsp;&nbsp;&nbsp;Common Stock, $0.01 par value; 100,000,000 shares authorized, 46,760,016 and 42,293,907 shares issued, 46,656,976 and 42,190,867 outstanding as of December 31, 2025 and 2024, respectively | 467600 | 422939 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 251455616 | 230508339 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (228603075) | (239850931) |
| &nbsp;&nbsp;&nbsp;Treasury stock, 103,040 shares, at cost, as of December 31, 2025 and 2024 | (163701) | (163701) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total LifeMD, Inc. Stockholders' Equity (Deficit) | 23156580 | (9083214) |
| Non-controlling interest of discontinued operations | - | 1529094 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Stockholders' Equity (Deficit) | 23156580 | (7554120) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities and Stockholders' Equity (Deficit) | $70411319 | $76096297 |

---

**LIFEMD, INC.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fourth Quarter Ended December 31,** | **Fourth Quarter Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | 2025 | 2024 | 2025 | 2024 |
| Telehealth revenue, net | $46868484 | $45137021 | $194055198 | $154824075 |
| Cost of telehealth revenue | 6025408 | 8391484 | 27714808 | 21440799 |
| **Gross profit** | 40843076 | 36745537 | 166340390 | 133383276 |
| **Expenses** |  |  |  |  |
| Selling and marketing expenses | 19086443 | 17819834 | 86074473 | 70102961 |
| General and administrative expenses | 15541255 | 16603620 | 57937023 | 57947932 |
| Customer service expenses | 2493087 | 2831985 | 11579636 | 10217654 |
| Other operating expenses | 3000591 | 2663872 | 11073155 | 8659712 |
| Development costs | 1819418 | 1670906 | 7345797 | 6857005 |
| &nbsp;&nbsp;&nbsp;Total expenses | 41940794 | 41590217 | 174010084 | 153785264 |
| **Operating loss from continuing operations** | (1097718) | (4844680) | (7669694) | (20401988) |
| **Other expenses** |  |  |  |  |
| Interest expense, net | 24079 | (610954) | (1360967) | (2175405) |
| Loss on debt extinguishment | - | - | (1155851) | - |
| **Loss from continuing operations before income taxes** | (1073639) | (5455634) | (10186512) | (22577393) |
| Income tax provision | (13898) | (598000) | (45721) | (598000) |
| **Net loss from continuing operations** | (1087537) | (6053634) | (10232233) | (23175393) |
| Net income from discontinued operations | 21030505 | 1426807 | 25852024 | 2315252 |
| **Net income (loss)** | 19942968 | (4626827) | 15619791 | (20860141) |
| Net (loss) income attributable to noncontrolling interests of discontinued operations | (20697) | 311838 | 1265685 | 548875 |
| **Net income (loss) attributable to LifeMD, Inc.** | 19963665 | (4938665) | 14354106 | (21409016) |
| Preferred stock dividends | (776562) | (776562) | (3106250) | (3106250) |
| **Net income (loss) attributable to LifeMD, Inc. common stockholders** | $19187103 | $(5715227) | $11247856 | $(24515266) |
| **Basic earnings (loss) per share attributable to LifeMD, Inc. common stockholders** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Continuing operations | $(0.04) | $(0.16) | $(0.30) | $(0.64) |
| &nbsp;&nbsp;&nbsp;Discontinued operations | 0.45 | 0.03 | 0.54 | 0.04 |
| &nbsp;&nbsp;&nbsp;Basic earnings (loss) per share | $0.41 | $(0.14) | $0.25 | $(0.60) |
| **Diluted earnings (loss) per share attributable to LifeMD, Inc. common stockholders** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Continuing operations | $(0.04) | $(0.16) | $(0.30) | $(0.64) |
| &nbsp;&nbsp;&nbsp;Discontinued operations | 0.45 | 0.03 | 0.54 | 0.04 |
| &nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share | $0.41 | $(0.14) | $0.25 | $(0.60) |
| **Weighted average number of common shares outstanding:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 46773743 | 42205767 | 45129617 | 41196292 |
| &nbsp;&nbsp;&nbsp;Diluted | 46773743 | 42205767 | 45129617 | 41196292 |

---

**LIFEMD, INC.**

 **CONSOLIDATED STATEMENTS OF CASH FLOWS** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fourth Quarter Ended December 31,** | **Fourth Quarter Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | 2025 | 2024 | 2025 | 2024 |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |  |  |
| Net income (loss) | $19942968 | $(4626827) | $15619791 | $(20860141) |
| Less: Net income from discontinued operations | 21030505 | 1426807 | 25852024 | 2315252 |
| Net loss from continuing operations | (1087537) | (6053634) | (10232233) | (23175393) |
| Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amortization of debt discount |  | 100444 | 234369 | 401775 |
| &nbsp;&nbsp;&nbsp;Amortization of capitalized software | 1636200 | 1481039 | 6348932 | 5696865 |
| &nbsp;&nbsp;&nbsp;Amortization of intangibles | 31918 | 6666 | 94002 | 26667 |
| &nbsp;&nbsp;&nbsp;Accretion of consideration payable |  |  |  | 13644 |
| &nbsp;&nbsp;&nbsp;Depreciation of fixed assets | 281609 | 159380 | 865524 | 465830 |
| &nbsp;&nbsp;&nbsp;Write-down of inventory |  | 675669 |  | 675669 |
| &nbsp;&nbsp;&nbsp;Loss on debt extinguishment |  |  | 1155851 |  |
| &nbsp;&nbsp;&nbsp;Noncash operating lease expense | 217495 | 220622 | 960702 | 672983 |
| &nbsp;&nbsp;&nbsp;Stock compensation expense | 2655143 | 3104956 | 10496321 | 12234797 |
| Changes in Assets and Liabilities |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable | (363895) | 661327 | 1150536 | (4487546) |
| &nbsp;&nbsp;&nbsp;Product deposit | 50301 | 95992 | (279454) | 445087 |
| &nbsp;&nbsp;&nbsp;Inventory | 658806 | (827584) | 23782 | (713095) |
| &nbsp;&nbsp;&nbsp;Other current assets | 915702 | (121682) | 357463 | (2270374) |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities | (103449) | (13780) | (275290) | (381189) |
| &nbsp;&nbsp;&nbsp;Deferred revenue | (1340226) | (933283) | (6290081) | 9826219 |
| &nbsp;&nbsp;&nbsp;Accounts payable | (651595) | 1043605 | 3244483 | 4176113 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | (4998738) | 662521 | (5782603) | 10755261 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by operating activities of continuing operations | (2098266) | 262258 | 2072304 | 14363313 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by operating activities of discontinued operations | (1182257) | 811043 | 6207871 | 3149877 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by operating activities | (3280523) | 1073301 | 8280175 | 17513190 |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |  |  |
| Cash paid for capitalized software costs | (1763287) | (1601100) | (7647959) | (6738742) |
| Purchase of equipment | (190704) | (212287) | (1870668) | (1463357) |
| &nbsp;&nbsp;&nbsp;Net cash used in investing activities of continuing operations | (1953991) | (1813387) | (9518627) | (8202099) |
| &nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities of discontinued operations | 19023623 | (907340) | 16426858 | (3334219) |
| &nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | 17069632 | (2720727) | 6908231 | (11536318) |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |  |  |
| Repayment of debt instruments |  |  | (18719721) |  |
| Sale of common stock under ATM, net |  |  | 8721717 |  |
| Repayment of notes payable, net of prepayment penalty |  |  |  | (327597) |
| Cash proceeds from exercise of warrants |  |  | 464950 |  |
| Cash proceeds from exercise of options |  | 12499 | 5950 | 120312 |
| Preferred stock dividends | (776562) | (776562) | (3106250) | (3106250) |
| &nbsp;&nbsp;&nbsp;Net cash used in financing activities of continuing operations | (776562) | (764063) | (12633354) | (3313535) |
| &nbsp;&nbsp;&nbsp;Net cash used in financing activities of discontinued operations | (12000) | (170840) | (773658) | (805138) |
| &nbsp;&nbsp;&nbsp;Net cash used in financing activities | (788562) | (934903) | (13407012) | (4118673) |
| Net increase (decrease) in cash | 13000547 | (2582329) | 1781394 | 1858199 |
| Cash at beginning of period | 23785771 | 37587253 | 35004924 | 33146725 |
| Cash at end of year | 36786318 | 35004924 | 36786318 | 35004924 |
| Less: Cash of discontinued operations at end of year | - | 2353123 | - | 2353123 |
| Cash of continuing operations at end of year | $36786318 | $32651801 | $36786318 | $32651801 |
| <u>Cash paid for interest and taxes</u> |  |  |  |  |
| Cash paid during the period for interest | $- | $614993 | $1461032 | $2528042 |
| Cash paid during the period for taxes | $184791 | $16035 | $667262 | $214211 |
| <u>Non-cash investing and financing activities:</u> |  |  |  |  |
| Cashless exercise of options | $- | $- | $1315 | $5127 |
| Cashless exercise of warrants | $- | $- | $3901 | $16305 |
| Stock issued for debt conversion | $- | $- | $1000000 | $- |
| Stock issued for asset acquisition | $- | $- | $303000 | $- |
| Stock issued for noncontingent consideration payments | $- | $- | $- | $642000 |
| Operating lease liabilities arising from obtaining right of use assets | $- | $(102618) | $- | $6372148 |

---

**About the Use of Non-GAAP Financial Measures:**

To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of this financial measure enhances an investor's understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.

Adjusted EBITDA is defined as net income (loss) attributable to LifeMD, Inc. common stockholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests of discontinued operations, extraordinary litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses, stock-based compensation expense and net income from discontinued operations. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to LifeMD, Inc. common stockholders, its most directly comparable GAAP financial measure.

We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.

**Reconciliation of Net Income (Loss) Attributable to LifeMD, Inc. Common Stockholders to Adjusted EBITDA**

**(in whole numbers, unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fourth Quarter Ended December 31,** | **Fourth Quarter Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) attributable to LifeMD, Inc. common stockholders | $19187103 | $(5715227) | $11247856 | $(24515266) |
| Interest (income) expense (excluding amortization of debt discount) | (24079) | 510510 | 1126598 | 1773630 |
| Depreciation, amortization and accretion expense | 1949727 | 1647085 | 7308458 | 6203006 |
| Amortization of debt discount |  | 100444 | 234369 | 401775 |
| Loss on debt extinguishment |  |  | 1155851 |  |
| Financing transactions expense | 36716 | 13125 | 134415 | 336497 |
| Litigation costs <sup>(a)</sup> | 573894 | 376030 | 2273355 | 1698531 |
| Severance costs | 266863 |  | 369280 | 1142068 |
| Acquisitions expenses | 211836 | 537662 | 1995042 | 537662 |
| Insurance acceptance readiness |  | 92661 | 183330 | 1454298 |
| Sarbanes Oxley readiness |  | 134891 |  | 521361 |
| Taxes | 176925 | 598000 | 208748 | 598000 |
| Preferred stock dividends | 776562 | 776562 | 3106250 | 3106250 |
| Stock compensation expense | 2655143 | 3104956 | 10496321 | 12234797 |
| Net income from discontinued operations | (21030505) | (1426807) | (25852024) | (2315252) |
| Net (loss) income attributable to noncontrolling interests of discontinued operations | (20697) | 311838 | 1265685 | 548875 |
| Adjusted EBITDA | $4759487 | $1061729 | $15253533 | $3726231 |

---

<sup>(a)</sup> For the fourth quarter and year ended December 31, 2025 and 2024, the Company included costs related to: (1) a class action complaint captioned *Johnston v. LifeMD, Inc., et al.*, against the Company and certain executive officers alleging: (i) violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder by all defendants for making false and misleading statements; and (ii) violations of Section 20(a) of the Securities Exchange Act of 1934, as amended, by the individual officer defendants for violating their duty to disseminate accurate and truthful information, (2) a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the *Marden v. LifeMD, Inc.* case), both disclosed in the Company's Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, and (3) a heavily negotiated executive separation agreement.

\# \# \#

## Exhibit 99.2

**Exhibit 99.2**

![](ex99-2_001.jpg)

![](ex99-2_002.jpg)

![](ex99-2_003.jpg)

![](ex99-2_004.jpg)

![](ex99-2_005.jpg)

![](ex99-2_006.jpg)

![](ex99-2_007.jpg)

![](ex99-2_008.jpg)

![](ex99-2_009.jpg)

![](ex99-2_010.jpg)

![](ex99-2_011.jpg)

![](ex99-2_012.jpg)

![](ex99-2_013.jpg)

![](ex99-2_014.jpg)

![](ex99-2_015.jpg)

![](ex99-2_016.jpg)

![](ex99-2_017.jpg)

![](ex99-2_018.jpg)

![](ex99-2_019.jpg)

![](ex99-2_020.jpg)

![](ex99-2_021.jpg)

![](ex99-2_022.jpg)

![](ex99-2_023.jpg)

![](ex99-2_024.jpg)

![](ex99-2_025.jpg)

![](ex99-2_026.jpg)